- TH9507 (ThGRF) in Phase III in HIV-associated lipodystrophy
- Sale of Celmed BioSciences
- $49 million in liquidities (pro forma)
MONTREAL, July 13 /CNW Telbec/ - Theratechnologies (TSX: TH) announced
today its financial results for the second quarter ended May 31, 2005 and
reviewed recent highlights.
"Through the first half of the year we made solid progress on our
objectives for 2005 and on the longer-term goal of building value for
shareholders," stated Yves Rosconi, President and Chief Executive Officer.
"Our top priority was to initiate the Phase III program and this was
accomplished in June with the first patient beginning treatment in Atlanta,
Georgia. On the financial side, we sold our investment in Celmed BioSciences,
which generated non-dilutive capital and tightened our business focus. We also
completed our management team on schedule bringing two additional
pharmaceutical executives on board. Looking ahead to the next six months, we
will be choosing a second indication for TH9507 and completing the strategic
assessment of our diabetes portfolio," he stated.
Operating highlights:
HIV-associated lipodystrophy
The first patient in the Phase III trial testing TH9507 in HIV-associated
lipodystrophy began treatment in June in Atlanta, Georgia. This disease is
often characterized by an accumulation visceral adipose tissue (VAT),
dyslipidemia and glucose intolerance. Among the 1.1 million HIV-positive
patients in North America and Europe, nearly 200,000 suffer from lipodystrophy
with excess VAT accumulation. The Phase III clinical trial is investigating
the safety and efficacy of TH9507 in reducing excess VAT in approximately
400 patients by administering 2 mg daily for a period of 26 weeks. Results are
expected in the second half of 2006.
Type 2 diabetes program (GLP-1 analogues)
In keeping with its overall strategic approach, Theratechnologies is
currently assessing its market positioning to determine the potential impact
of recent clinical developments involving other GLP-1 analogues. A decision on
the next steps to be taken will be made in the second half of the year.
Sale of investment in Celmed BioSciences
On June 20, the Company completed the sale of its 37% interest in Celmed
Biosciences, a privately held oncology company, for a total consideration of
up to $8.4 million. Total consideration includes an upfront payment of
$2.8 million and milestone payments tied to the success of Celmed's lead
products.
$49 million in liquidities
At May 31, 2005, liquidities (cash, cash equivalents as well as bonds)
amounted to $45.0 million, and tax credits and grants receivable amounted to
$1.2 million, for a total of $46.2 million. Adding the $2.6 million
($2.8 million less related expenses) from the sale of the Celmed shares, the
pro forma liquidities (including the Company's tax credits receivable) would
be $48.8 million. Based on the current burn rate, the Company would be able to
fund its operations for the next three years.
Analyst day
On May 27, the company held an analyst day in Toronto on its Phase III
program in HIV-associated lipodystrophy. The half-day meeting featured
presentations on the disease by Dr. Julian Falutz, lead investigator for the
proposed Canadian study, and Dr. Steven Grinspoon, lead investigator for the
United States. Company management presented clinical and financial details of
the study, as well as the important findings from market research on the
disease. The participants reported back that they were very satisfied with the
information presented.
Four scientific posters at Endo 2005
Researchers from Theratechnologies presented four scientific posters at
the 87th Annual Meeting of the Endocrine Society held in San Diego from
June 4th to June 7th. The posters included data on the lead product, TH9507,
as well as early-stage data related to the diabetes program. The Endocrine
Society's annual meeting is internationally known as the leading source of
state-of-the-art research and clinical advancement in endocrinology and
metabolism.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL CONDITION:
Consolidation and investments
The consolidated financial statements include the accounts of
Theratechnologies and its subsidiaries. Since July 2nd, 2004, the Company no
longer exercises control over Celmed and the interest in this company is
accounted for by the equity method. Theratechnologies' 2004 consolidated
results include Celmed's results until that date (see note 2 in the notes to
the consolidated financial statements).
Summary of operating results
Consolidated revenues for the three-month period ended May 31, 2005
amounted to $631,000, compared to $782,000 ($555,000 without Celmed) for the
same period in 2004. For the six-month period ended May 31, 2005, consolidated
revenues were $15,733,000, compared to $1,561,000 ($1,074,000 without Celmed)
for the corresponding period in 2004. The increase during the first half of
the year is essentially due to the payment of $14,640,000 (US$12,000,000)
received in connection with the Company's December 2004 agreement with ALZA to
terminate three co-development projects using ALZA's Macroflux(R) transdermal
technology.
Consolidated research and development (R&D) expenditures, before tax
credits and grants, for the second quarter of 2005, totaled $3,246,000,
compared to $5,675,000 ($3,913,000 without Celmed) in 2004. For the six-month
period ended May 31, 2005, R&D expenses reached $6,466,000, compared to
$11,565,000 ($8,012,000 without Celmed). The higher level of expenditures in
2004 is mostly related to activities surrounding ThPTH and TH0318, a GLP-1
analogue (glucagons-like peptide-1). Activities relating to ThPTH ceased
following the agreement with ALZA in December 2004. Development of TH0318 has
been stopped in order to allow the Company to assess its market positioning in
type 2 diabetes.
During the first half of 2005, management reassessed its strategy
regarding non-core products and the related patent portfolio. As a result, the
Company recorded a write off of $444,000 of certain patent costs and deferred
development expenses.
For the second quarter, general and administrative expenses, selling and
market development expenses, patents and amortization of other assets (SG&A)
were $2,425,000 ($1,981,000 before the adjustment to book value of patents and
deferred development expenses referred to above), compared to $2,525,000
($1,685,000 without Celmed) for the same period in 2004. For the six month
period ended May 31, 2005, SG&A expenses were $4,121,000 ($3,677,000 before
the book value adjustment), compared to $4,841,000 ($3,014,000 without Celmed)
for the same period in 2004. The increase in SG&A expenses is mainly due to
preparations required for late-stage development and future commercialization
of TH9507.
For the second quarter of 2005, the proportionate share in loss of Celmed
and Andromed was $5,302,000, compared to $234,000 in 2004. For the six-month
period ended May 31, 2005, the proportionate share in loss of Celmed and
Andromed was $6,449,000, compared to $493,000 in 2004. This increase in the
proportionate share in loss of companies under significant influence is due to
the change to the equity method of accounting of the interest in Celmed, which
only began in the third quarter of fiscal 2004 (see note 2 in the notes to the
consolidated financial statements). In 2004, therefore, the figures represent
only the Company's share of losses in Andromed. This increase is also due to
the non-cash write down, net of related income taxes, of $9,685,000 recorded
by Celmed at May 31, 2005 in connection with the acquisition of NewBiotics'
intellectual property in 2004.
On June 20, 2005, the Company completed the sale of its 37,3% interest in
Celmed BioSciences for total proceeds of up to $8,400,000. The proceeds
include an upfront payment of $2,811,000, as well as milestone payments tied
to the success of Celmed's more advanced products totalling $5,589,000. The
milestone payments will be recorded once the related milestones are reached.
The book value of the investment in Celmed at May 31st reflects the upfront
payment, less the related expenses. Consequently, a non-cash write down of
$2,659,000 was recorded in the second quarter.
The Company recorded an operating loss for the three-month period ended
May 31, 2005 of $4,784,000 (before proportionate share in loss of companies
under significant influence and gains on investments in companies and gains on
dilution, non-controlling interest and discontinued operations), compared to
an operating loss of $6,832,000 for the same period in 2004. The net loss for
the second quarter of 2005 was $12,745,000, compared to a net loss of
$5,910,000 in 2004. For the six-month period ended May 31, 2005, the net loss
was $3,474,000, compared to $7,793,000 in 2004.
Quarterly financial information
The selected financial information provided below is derived from the
Company's unaudited quarterly financial statements for each of the last eight
quarters. This quarterly information has been restated pursuant to the change
in accounting policy related to stock-based remuneration and other payments
described in the 2004 Annual Report, and in order to account for discontinued
operations. This information includes Celmed's results until July 2, 2004.
(See note 2 in the notes to the consolidated financial statements).
<<
-------------------------------------------------------------------------
-------------------------------------------------------------------------
2005
-------------------------------------------------------------------------
Q2 Q1
-------------------------------------------------------------------------
Revenues $ 631 $ 15,102
Operating
earnings (loss) (1) $ (4,784) $ 10,418
Earnings (loss)
from continuing
operations (2) $ (12,745) $ 9,271
Net earnings
(loss) $ (12,745) $ 9,271
Basic and diluted
earnings (loss)
per share:
Continuing
activities (2) $ (0.36) $ 0.26
Net earnings (loss) $ (0.36) $ 0.26
-------------------------------------------------------------------------
-------------------------------------------------------------------------
-------------------------------------------------------------------------
-------------------------------------------------------------------------
2004
-------------------------------------------------------------------------
Q4 Q3 Q2 Q1
-------------------------------------------------------------------------
Revenues $ 503 $ 585 $ 782 $ 779
Operating
earnings (loss) (1) $ (4,655) $ (4,289) $ (6,832) $ (7,094)
Earnings (loss)
from continuing
operations (2) $ (10,873) $ (4,137) $ (6,139) $ (1,731)
Net earnings
(loss) $ (10,873) $ (4,150) $ (5,910) $ (1,883)
Basic and diluted
earnings (loss)
per share:
Continuing
activities (2) $ (0.31) $ (0.12) $ (0.17) $ (0.06)
Net earnings (loss) $ (0.31) $ (0.12) $ (0.17) $ (0.06)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
-------------------------------------------------------------------------
-------------------------------------------------------------------------
2003
-------------------------------------------------------------------------
Q4 Q3
-------------------------------------------------------------------------
Revenues $ 897 $ 941
Operating
earnings (loss) (1) $ (7,805) $ (6,694)
Earnings (loss)
from continuing
operations (2) $ (7,771) $ (6,232)
Net earnings
(loss) $ (14,079) $ (6,581)
Basic and diluted
earnings (loss)
per share:
Continuing
activities (2) $ (0.25) $ (0.20)
Net earnings (loss) $ (0.46) $ (0.21)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(1) Before restructuring costs, proportionate share in loss of a company
under significant influence, gains on investments in companies and
gains on dilution, discontinued operations and non-controlling
interest
(2) Net of non-controlling interest
Financial position
Theratechnologies maintains a sound cash position. At May 31, 2005,
liquidities (cash and cash equivalents as well as bonds) amounted to
$45,009,000 and tax credits and grants receivable amounted to $1,246,000, for
a total of $46,255,000. Adding the $2,565,000 ($2,811,000 less related
expenses) from the sale of the investment in Celmed the pro forma liquidities
(including the Company's tax credits receivable) would be $48,820,000.
For the three-month period ended May 31, 2005, the burn rate from
operating activities, excluding changes in operating assets and liabilities,
was $3,953,000, compared to a burn rate of $6,138,000 ($4,101,000 without
Celmed) in 2004. For the six-month period ended May 31, 2005, cash from
operating activities, excluding changes in operating assets and liabilities,
was $6,755,000, compared to a burn rate of $12,608,000 ($8,390,000 without
Celmed) in 2004, reflecting the payment from ALZA and lower R&D expenses as
described above.
At July 12, 2005, the number of shares issued and outstanding was
35,549,019, while outstanding options granted under the stock option plan were
2,488,161. In addition, 1,280,000 warrants were outstanding.
During the quarter, there were no material changes in contractual
obligations, other than in the ordinary course of business.
Economic and industry factors were substantially unchanged from those
reported in the Company's 2004 annual report.
About Theratechnologies
Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company
engaged in the discovery and development of therapeutic peptides in the field
of endocrinology and metabolism. The Company uses proprietary discovery
technologies to expand its product portfolio. The most advanced clinical
program (Phase III) targets HIV-associated lipodystrophy with its lead
compound, TH9507 (ThGRF). The Company is evaluating other potential
indications for TH9507 and it has an interesting product pipeline targeting
type 2 diabetes.
Additional information about Theratechnologies
Further information relating to Theratechnologies is available on the
Company's website at http://www.theratech.com/ . The Company is listed on the
Toronto Stock Exchange under the symbol TH. Additional information, including
the Company's Annual Information Form, is available on SEDAR at
www.sedar.com .
This press release contains forward-looking statements that reflect
Company's current views with respect to its short-term objectives. These
statements involve numerous risks and uncertainties and the Company does not
undertake to update this information. Investors are cautioned against placing
undue importance on forward-looking information contained herein and should
consult the Company's 2004 Annual Report, which contains a analysis of risks
and uncertainties connected to the businesses of the Company.
THERATECHNOLOGIES INC.
CONSOLIDATED BALANCE SHEET
(in thousands of dollars)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
May 31 November 30
2005 2004
-------------------------------------------------------------------------
(unaudited) (audited)
Assets
Current assets:
Cash and cash equivalents $ 7,599 $ 436
Bonds 11,677 17,513
Accounts receivable 345 395
Tax credits receivable 1,246 754
Research supplies 2,620 1,542
Prepaid expenses 597 202
-------------------------------------------------------------------------
24,084 20,842
Bonds 25,733 24,105
Investments in public companies
(market value : $2,759 in 2005; $3,026 in 2004) 1,060 1,362
Investment in a private company (note 2) 2,565 11,367
Property and equipment 2,280 2,234
Other assets (note 3) 8,101 8,040
-------------------------------------------------------------------------
$ 63,823 $ 67,950
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable and accrued liabilities $ 4,120 $ 4,996
Shareholders' equity:
Capital stock (note 4) 155,654 155,594
Contributed surplus 2,420 2,257
Deficit (98,371) (94,897)
-------------------------------------------------------------------------
59,703 62,954
Subsequent event (note 10)
-------------------------------------------------------------------------
$ 63,823 $ 67,950
-------------------------------------------------------------------------
-------------------------------------------------------------------------
See accompanying notes to unaudited consolidated financial statements.
THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENT OF EARNINGS
PERIODS ENDED MAY 31
(in thousands of dollars, except per share amounts) (unaudited)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Second quarter Six months
2005 2004 2005 2004
-------------------------------------------------------------------------
Revenues:
Royalties,
technologies and
other (note 5) $ 158 $ 60 $ 14,830 $ 139
Interest 473 722 903 1,422
-------------------------------------------------------------------------
631 782 15,733 1,561
Operating costs
and expenses:
Research and
development 3,246 5,675 6,466 11,565
Tax credits (256) (586) (488) (919)
-------------------------------------------------------------------------
2,990 5,089 5,978 10,646
General and
administrative 1,364 2,025 2,687 3,987
Selling and market
development 363 293 585 446
"Patents and amortization
of other assets
(note 3)" 698 207 849 408
-------------------------------------------------------------------------
5,415 7,614 10,099 15,487
-------------------------------------------------------------------------
Operating (loss)
earnings before
undernoted items (4,784) (6,832) 5,634 (13,926)
Proportionate share in loss
of companies under
significant influence (5,302) (234) (6,449) (493)
(Loss) gains on investments
in companies and gains
on dilution (note 6) (2,659) 89 (2,659) 4,743
-------------------------------------------------------------------------
Loss from continuing
operations before
non-controlling
interest (12,745) (6,977) (3,474) (9,676)
Gain from discontinued
operations (note 7) - 386 - 131
Non-controlling interest - 681 - 1,752
-------------------------------------------------------------------------
Net loss $ (12,745) $ (5,910) $ (3,474) $ (7,793)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Basic and diluted loss
per share (note 4 b):
Continuing operations
net of non-
controlling
interest $ (0.36) $ (0.18) $ (0.10) $ (0.24)
Discontinued operations
net of non-
controlling
interest $ - $ 0.01 $ - $ 0.01
Net loss $ (0.36) $ (0.17) $ (0.10) $ (0.23)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Weighted average
number of common
shares outstanding 35,524,730 35,466,118 35,519,201 33,470,291
-------------------------------------------------------------------------
-------------------------------------------------------------------------
See accompanying notes to consolidated financial statements.
THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
PERIODS ENDED MAY 31
(in thousands of dollars) (unaudited)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Second quarter Six months
2005 2004 2005 2004
-------------------------------------------------------------------------
Cash flows from operating
activities:
Net loss $ (12,745) $ (5,910) $ (3,474) $ (7,793)
Adjustments for:
Depreciation of
property and
equipment 139 271 275 533
Depreciation of
other assets 563 137 683 268
Stock-based
compensation 129 286 163 517
Proportionate
share in loss
of companies
under significant
influence 5,302 234 6,449 493
Loss (gains) on
investments in
companies and
gains on dilution 2,659 (89) 2,659 (4,743)
Gain from discontinued
operations - (386) - (131)
Non-controlling
interest - (681) - (1,752)
-------------------------------------------------------------------------
(3,953) (6,138) 6,755 (12,608)
Change in operating
assets and liabilities:
Interest receivable
on bonds 267 (405) 46 (39)
Accounts receivable 90 (170) 50 (148)
Tax credits (260) (584) (492) (913)
Research supplies 25 155 (1,738) 274
Prepaid expenses (311) (273) (395) (546)
Accounts payable
and accrued
liabilities (1,625) (1,485) (710) (1,762)
-------------------------------------------------------------------------
(1,814) (2,762) (3,239) (3,134)
Cash used in
discontinued
operations - (110) - (406)
-------------------------------------------------------------------------
(5,767) (9,010) 3,516 (16,148)
Cash flows from
financing activities:
Share issue 60 49 60 15,721
Share issue costs - (145) - (1,127)
-------------------------------------------------------------------------
60 (96) 60 14,594
Cash flows from
investing activities:
Addition to property
and equipment (101) (138) (380) (378)
Disposal of property
and equipment - - - 122
Addition to other assets (67) (348) (191) (387)
Acquisition of bonds - (17,083) (7,389) (26,102)
Disposal of bonds 7,926 8,871 11,551 29,344
Fees related to the
disposal of shares
in a private company (4) - (4) -
Disposal of shares in
public companies - 112 - 2,481
Net investments related
to discontinued
operations - 10 - 10
-------------------------------------------------------------------------
7,754 (8,576) 3,587 5,090
-------------------------------------------------------------------------
Net change in cash and
cash equivalents 2,047 (17,682) 7,163 3,536
Cash and cash
equivalents, beginning
of period 5,552 21,271 436 53
-------------------------------------------------------------------------
Cash and cash
equivalents, end
of period $ 7,599 $ 3,589 $ 7,599 $ 3,589
-------------------------------------------------------------------------
-------------------------------------------------------------------------
See accompanying notes to consolidated financial statements.
See note 9 a) for supplemental cash flow information.
THERATECHNOLOGIES INC.
CONSOLIDATED STATEMENTS OF DEFICIT
SIX-MONTH PERIOD ENDED MAY 31
(in thousands of dollars) (unaudited)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
2005 2004
-------------------------------------------------------------------------
Deficit, beginning of year $ (94,897) $ (70,922)
Net loss (3,474) (7,793)
Share issue costs - (1,171)
-------------------------------------------------------------------------
Deficit, end of period $ (98,371) $ (79,886)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
See accompanying notes to consolidated financial statements.
THERATECHNOLOGIES INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
PERIODS ENDED MAY 31, 2005
(in thousands of dollars, except per share amounts) (unaudited)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
1. Basis of presentation
The financial statements included in this report are unaudited and
reflect normal and recurring adjustments, which are in the opinion of the
Company, considered necessary for a fair presentation. These financial
statements have been prepared in conformity with Canadian generally accepted
accounting principles. The same accounting policies as described in the
Company's latest annual report have been used. However, these financial
statements do not include all disclosures required under generally accepted
accounting principles and accordingly should be read in connection with the
financial statements and the notes thereto included in the Company's latest
annual report. These interim financial statements have not been reviewed by
auditors.
2. Significant accounting policies
Consolidation and investments
The consolidated financial statements include the accounts of the Company
and its subsidiaries. All significant intercompany transactions and balances
have been eliminated.
The investment in public companies is composed of the investment in
Andromed Inc. ("Andromed") and in Ecopia BioSciences Inc. ("Ecopia").
The investment in Andromed Inc. ("Andromed"), a company under significant
influence, has been accounted for by the equity method. The investment in
Ecopia BioSciences Inc., a portfolio investment, is recorded at cost.
On July 2, 2004, Celmed BioSciences Inc. ("Celmed") acquired NewBiotics
Inc. and issued shares from its capital stock to the shareholders of the
acquired company. Consequently, Theratechnologies' interest in Celmed
decreased from 59.7% to 42%. An adjustment clause in connection with the
interest of founding investors could reduce the Company's interest to 37.3%.
Since the date of this transaction, the Company no longer exercises control
over Celmed and the interest in this company is accounted for by the equity
method.
In June 2005, Theratechnologies sold the totality of its shares in Celmed
(see note 10). As of May 31, 2005, the investment in this company is recorded
at the upfront payments to be received amount less related expenses.
3. Other assets
During the first half of 2005, management reassessed its strategy
regarding non-core products and the related patent portfolio. As a result, the
Company recorded a write off of $444 of certain patent costs and deferred
development expenses.
4. Capital stock
-------------------------------------------------------------------------
-------------------------------------------------------------------------
May 31 November 30
2005 2004
-------------------------------------------------------------------------
Authorized in unlimited number and
without par value:
Common shares
Preferred shares issuable in one
or more series
Issued:
35,549,019 common shares (35,513,549 in 2004) $ 155,654 $ 155,594
-------------------------------------------------------------------------
-------------------------------------------------------------------------
During the second quarter of 2005, the Company issued 35,470 shares for
cash consideration of $60.
a) Stock-based compensation and other stock-based payments
The weighted-average fair value of the 415,000 options granted during the
six-month period ended May 31, 2005 is $0.97 per option. The fair value of the
options granted during 2005 was estimated at the date of grant using the
Black-Scholes option pricing model with the following assumptions: risk-free
interest rate of 3.77%, expected dividend yield of nil, expected volatility of
51% and an average expected option life of 6 years.
b) Diluted loss per share
Diluted loss per share were not presented as the effect of options and
warrants would have been anti-dilutive. Furthermore, the exercise of options
and warrants would not have been considered in such computation since their
exercise prices were higher than the average market price during the reporting
periods of 2004 and 2005.
5. Royalties, technologies and other
In December 2004, the Company completed an agreement to terminate three
co-development projects using ALZA Corporation's Macroflux(R) transdermal
technology. The Company retains the rights to develop its molecules with all
other means of delivery and ALZA retains the commercialization rights to
Macroflux(R) with other molecules. In this regard, the Company received a
payment of $14,640 (US $12,000).
6. Loss (gains) on investments in companies and gains on dilution
During the quarters ended February 29, 2004 and May 31, 2004, the Company
realized gains on investments in companies of $1,929 and $89 respectively,
resulting from the sale of shares in public companies.
In January and February 2004, Celmed's institutional investors exercised
adjustment clauses in relation to their investment, thus reducing the
Company's interest in Celmed from 61.6% to 56.1%. In February 2004, Celmed
proceeded with the redemption for a nominal amount of shares of certain
shareholders because the milestones related to these shares were not achieved.
In April 2004, Celmed proceeded with the redemption of shares of a
non-controlling shareholder in connection with the sale of a US subsidiary.
These redemptions resulted in an increase of the Company's interest in Celmed
to 59.7%.
Consequently, the deferred gain of $3,762 at November 30, 2003 was
attributed to non-controlling interests, and the adjustment to their interest
resulted in a gain of $2,725, which is included in the statement of earnings
for the period ended February 29, 2004.
On May 31, 2005, the Company recorded a reduction in value of $2,659 in
relation to the sale of its shares in Celmed on June 20, 2005 (see note 10).
7. Discontinued operations
During the first quarter of 2004, Celmed studied the relevance of
pursuing its activities in the treatment of Parkinson's disease. In this
context, Celmed discontinued its development activities for this program. In
April 2004, Celmed disposed of the shares of its US subsidiary in the field of
neurology.
Consequently, operating results for these activities have been
reclassified under item "Discontinued operations". The results are shown
below:
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Second quarter Six months
2005 2004 2005 2004
-------------------------------------------------------------------------
Costs and expenses:
General and
administrative $ - $ (58) $ - $ (42)
Research and
development - 104 - 322
Patents and
amortization of
other assets - - - 21
Gain on disposal
of subsidiary - (432) - (432)
-------------------------------------------------------------------------
Gain from
discontinued
operations $ - $ 386 $ - $ 131
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Gain from
discontinued
operations
attributable to
parent company $ - $ 229 $ - $ 77
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Non-controlling
interest before
discontinued
activities $ - $ 838 $ - $ 1,806
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Loss from
continuing
operations, net
of non-controlling
interest $ (12,745) $ (6,139) $ (3,474) $ (7,870)
-------------------------------------------------------------------------
-------------------------------------------------------------------------
8. Segmented information
-------------------------------------------------------------------------
Intersegment
adjustments
Therapeutic Cell Other and
peptides therapy segments eliminations Total
-------------------------------------------------------------------------
Second quarter
ended May 31, 2005
Revenues from
external
customers $ 150 $ - $ - $ - $ 150
Revenues from
companies under
significant
influence 8 - - - 8
Loss from
continuing
operations (4,784) (5,149) (153) (2,659) (12,745)
Net loss (4,784) (5,149) (153) (2,659) (12,745)
Total assets 60,527 2,565 1,060 (329) 63,823
Six months ended
May 31, 2005
Revenues from
external
customers $ 14,810 $ - $ - $ - $ 14,810
Revenues from
companies under
significant
influence 20 - - - 20
Earnings (loss)
from continuing
operations 5,634 (6,147) (302) (2,659) (3,474)
Net earnings
(net loss) 5,634 (6,147) (302) (2,659) (3,474)
Total assets 60,527 2,565 1,060 (329) 63,823
-------------------------------------------------------------------------
-------------------------------------------------------------------------
-------------------------------------------------------------------------
Intersegment
Cell adjustments
Therapeutic therapy Other and
peptides (1) segments eliminations Total
-------------------------------------------------------------------------
Second quarter
ended May 31, 2004
Revenues from
external
customers $ 60 $ - $ - $ - $ 60
Intersegment
revenues 21 - - (21) -
Loss from
continuing
operations (4,587) (1,892) (234) 574 (6,139)
Net loss (4,587) (1,663) (234) 574 (5,910)
Total assets 62,251 31,579 1,439 (112) 95,157
Six months ended
May 31, 2004
Revenues from
external
customers $ 139 $ - $ - $ - $ 139
Intersegment
revenues 42 - - (42) -
Loss from
continuing
operations (9,284) (4,392) (493) 6,299 (7,870)
Net Loss (9,284) (4,315) (493) 6,299 (7,793)
Total assets 62,251 31,579 1,439 (112) 95,157
-------------------------------------------------------------------------
-------------------------------------------------------------------------
(1) The 2004 net loss for this sector was reduced by the non-controlling
interest.
9. Supplemental information
a) The following transactions were concluded by the Company and did not
impact cash flow.
-------------------------------------------------------------------------
-------------------------------------------------------------------------
May 31 May 31
2005 2004
-------------------------------------------------------------------------
Addition to property and equipment financed
by accounts payable and accrued liabilities $ 190 $ 24
Addition to other assets financed by
accounts payable and accrued liabilities 22 388
Share issue cost financed by accounts
payable and accrued liabilities - 44
-------------------------------------------------------------------------
b) General and administrative expenses include a gain on exchange of
$47 for the second quarter of 2005 (loss of $5 in 2004) and a loss of
$3 for the six-month period ended May 31, 2005 (gain of $40 in 2004).
10. Subsequent event
On June 20, 2005, the Company completed the sale of its 37,3% interest in
Celmed BioSciences for total proceeds of up to $8,400. The acquirer is a group
of minority shareholders of Celmed.
The proceeds include an upfront payment of $2,811, as well as milestone
payments tied to the success of Celmed's more advanced products totalling
$5,589. The milestone payments will be recorded once the related milestones
are reached.
>>
Theratechnologies: Financial results for the second quarter and recent operating highlights
Story so far
Earlier from Theratechnologies
- Theratechnologies launches Phase III clinical trial for TH9507 (ThGRF) treating HIV-associated lipodystrophy
- Theratechnologies closes the sale of its investment in Celmed BioSciences
- Theratechnologies: four scientific posters at the Endocrine Society Annual Meeting
- Theratechnologies reports on a positive meeting with Health Canada for its ThGRF Phase III program
- PRESS CONFERENCE - Theratechnologies Inc. - Invitation to Media
Later from Theratechnologies
- European pharmaceutical executive joins the Board of Theratechnologies
- Theratechnologies: TH9507 Phase 3 study advancing rapidly
- Theratechnologies' common shares now eligible for inclusion in the SMB Growth Stock Plan
- Market Regulation Services - Trading Halt - Theratechnologies Inc. - TH
- Market Regulation Services - Trade Resumption - Theratechnologies Inc. - TH
Follow Theratechnologies into a list and get an email when it puts out news.
Follow Theratechnologies